Researchers from Children's National Medical Center and Yale University have shown that the transcription factor heat shock factor 1 was activated by multiple environmental stressors that can cause fetal brain damage. Read More
Actavis plc, of Dublin, and Forest Laboratories Inc., of New York, said each has received a request for additional information from the Federal Trade Commission (FTC) in connection with Actavis' pending acquisition of Forest. Read More
Navidea Biopharmaceuticals Inc. is testing Lymphoseek injection (technetium Tc 99m tilmanocept), its FDA-approved lymphatic mapping agent, in a head-to-head study with radiolabeled sulfur colloid to see which drug causes patients less pain. Read More
"The worst disease you've never heard of." That's how patient advocacy and nonprofit group Debra (Dystrophic Epidermolysis Bullosa Research Association of America) refer to epidermolysis bullosa (EB), a rare genetic disorder characterized by fragile skin that it often leaves its sufferers with chronic open wounds and blisters. Read More
Researchers have gained new insights into the cellular consequences of trisomy 21 by studying an unusual set of twins – one with the trisomy, which leads to Down syndrome, and one without. Read More
In Greek mythology, Telephus was a son of Heracles who received a wound in battle that would not heal until he returned to the Greek warrior, Achilles, who had inflicted the injury. He was healed by the very spear that had pierced him. Read More
TAIPEI, Taiwan – Taiwan Liposome Co. (TLC) and Ablynx NV are planning to jointly develop a new drug delivery technology combining TLC's immunoliposome platform with Ablynx' antibody-derived nanobody technology that will enable more precisely targeted delivery of liposome-encapsulated cytotoxic compounds to disease sites in cancer patients. Read More
